KALV

KalVista Pharmaceuticals, Inc.

11.85 USD
+0.13 (+1.11%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

KalVista Pharmaceuticals, Inc. stock is up 4.87% since 30 days ago. The next earnings date is Jul 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 June’s closed higher than May. 100% of analysts rate it a buy.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME) products.